SCHEMBL23368310

SCHEMBL23368310

COC(=O)C(NC(=O)CNC(=O)Cn1ncc2ccccc21)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.51
▸ RAB9A P51151 4/20 0.51
▸ POLB P06746 3/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ TSHR P16473 2/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.43
▸ TACR3 P29371 2/20 0.42
▸ KMO O15229 1/20 0.42
▸ MAPK1 P28482 3/20 0.41
▸ ADRB2 P07550 1/20 0.40
▸ ADRB1 P08588 1/20 0.40
▸ ADRB3 P13945 1/20 0.40
▸ RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23368380 0.86 NPC1 (0.54) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL23368381 0.84 NPC1 (0.52) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL23368379 0.84 NPC1 (0.49) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL23368378 0.82 NPC1 (0.50) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL23368382 0.80 TSHR (0.51) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL23368311 0.78 NPC1 (0.55) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL31602336 0.78 KMO (0.56) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL23368341 0.74 NPC1 (0.44) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL4300707 0.71 NPC1 (0.56) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL17445794 0.71 NPC1 (0.57) NPC1RAB9APOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3411411-B3 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2022-01-26 — — EP disclosed
EP-3411411-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2021-05-19 — — EP disclosed
Send feedback